바이오의약품 CMO 시장 규모, 점유율, 성장 및 산업 분석 : 유형별, 용도별, 지역별 인사이트 및 예측(2026-2034년)

Growth Factors of biopharmaceutical Contract Manufacturing Organization (CMO) Market

The global biopharmaceutical Contract Manufacturing Organization (CMO) market was valued at USD 19.00 billion in 2025 and is projected to reach USD 21.74 billion in 2026, ultimately growing to USD 70.36 billion by 2034, exhibiting a CAGR of 15.81% during the forecast period. North America dominated the market in 2025 with a 39.70% share, attributed to the high number of manufacturing facilities and strategic expansion initiatives by key market players.

Biopharmaceutical CMOs provide specialized services including drug development, manufacturing, analytical testing, and packaging. Outsourcing these processes allows biopharmaceutical companies to focus on core competencies such as research, development, and marketing while relying on CMOs for large-scale manufacturing. The demand for CMOs has grown significantly due to the rise of biologics, biosimilars, and complex therapies, along with technological advancements and stringent regulatory requirements.

Market Drivers

The primary driver of market growth is the rising demand for biologics and biosimilars. The shift from small-molecule drugs to large-molecule biopharmaceuticals, coupled with the increasing number of biologics approvals, has made CMOs essential for production. For example, in 2023, the U.S. FDA approved 55 new drug products, including 18 biologics, highlighting the increasing outsourcing needs.

Other key drivers include cost and time efficiency, as CMOs offer access to advanced equipment and skilled labor without significant capital investment. The growth of personalized medicine and targeted therapies, particularly in oncology, also fuels the demand for contract manufacturing services.

Market Restraints

High operational and infrastructure costs limit market growth. Establishing large-scale manufacturing facilities, especially stainless steel bioproduction plants, requires significant capital. Additionally, stringent regulatory compliance under cGMP regulations and supply chain vulnerabilities for raw materials pose challenges to efficient manufacturing.

Market Opportunities

The adoption of single-use bioprocessing technologies offers lucrative growth opportunities. Single-Use Bioreactors (SUBs) and disposable mixers provide flexibility, reduced cross-contamination risks, and faster turnaround times. Expanding manufacturing capabilities in emerging markets also presents opportunities for CMOs to capture untapped demand.

Market Trends

Key trends include continuous manufacturing, which integrates end-to-end production for increased efficiency, and the growing emphasis on digitalization and AI integration for process optimization. Strategic collaborations between CMOs and biopharmaceutical companies are rising, enabling co-investments, shared expertise, and enhanced production capabilities.

COVID-19 Impact

The pandemic positively influenced the market due to the surge in demand for contract manufacturing of COVID-19 vaccines. Several CMOs signed agreements with vaccine developers to produce both approved vaccines and clinical candidates. However, 2023-2024 saw a normalization in growth as COVID-19-related production demand declined.

Market Segmentation

By Service:

• Manufacturing services dominated in 2026 with 45.53% share, driven by the increasing number of contract manufacturing projects. Downstream processing held the largest share due to its complex technology requirements.
• Fill & finish operations, analytical & QC studies, and packaging are also growing, driven by product approvals and increased biologics launches.

By Source:

• Mammalian expression systems led with 71.16% share in 2026, due to their widespread use in biologics production. Non-mammalian systems are also growing, especially for microbial-based products.

By Product:

• Biologics dominated in 2026 with 93.18% share, fueled by increasing product approvals and a growing development pipeline.
• Biosimilars are projected to witness strong growth, particularly in cost-sensitive markets.

Regional Insights

• North America: Market size USD 7.53 billion in 2025 and USD 8.63 billion in 2026, led by the U.S. with USD 7.91 billion in 2026, supported by technology adoption and capacity expansion.
• Europe: Market projected to reach UK USD 1.51 billion and Germany USD 1.75 billion in 2026, with 37% of global CMO capacity.
• Asia Pacific: Fastest growth, driven by offshoring trends. Japan USD 0.62 billion, China USD 1.22 billion, India USD 0.75 billion in 2026.
• Latin America & Middle East/Africa: Smaller markets, but improving infrastructure is expected to boost adoption.

Key Players & Industry Developments

Prominent players include Lonza, Samsung Biologics, WuXi Biologics, Catalent Inc., FUJIFILM Diosynth Biotechnologies, Siegfried Holding AG, Recipharm AB, Cambrex, and Thermo Fisher Scientific. Strategic collaborations and investments are driving growth:

• Dec 2024: AGC Biologics' Milan Cell and Gene site approved by U.S. FDA for commercial manufacturing of AUCATZYL.
• Nov 2024: Samsung Biologics signed a Europe-based manufacturing agreement through 2031.
• Oct 2024: Lonza collaborated for commercial-scale manufacturing of ADCs.
• July 2024: Siegfried Holding acquired an early-phase CDMO in the U.S.

Conclusion

The biopharmaceutical CMO market is expected to expand from USD 19.00 billion in 2025 to USD 70.36 billion by 2034, at a CAGR of 15.81%, driven by increasing biologics approvals, rising outsourcing trends, adoption of advanced manufacturing technologies, and expansion into emerging markets. While high operational costs and regulatory challenges remain, continuous innovation, strategic partnerships, and digitalization will ensure robust growth across the forecast period.

Segmentation By Service

• Manufacturing
  • Upstream Processing
  • Downstream Processing
• Fill & Finish Operations
• Analytical & QC Studies
• Packaging

By Source

• Mammalian
• Non-mammalian

By Product

• Biologics
• Biosimilars

By Region

• North America (By Service, Source, Product, and Country)
  • U.S.
  • Canada
• Europe (By Service, Source, Product, and Country/Sub-Region)
  • Germany
  • U.K.
  • France
  • Italy
  • Spain
  • Scandinavia
  • Rest of Europe
• Asia Pacific (By Service, Source, Product, and Country/Sub-Region)
  • China
  • Japan
  • India
  • Australia
  • Southeast Asia
  • Rest of the Asia Pacific
• Latin America (By Service, Source, Product, and Country/Sub-Region)
  • Brazil
  • Mexico
  • Rest of Latin America
• Middle East & Africa (By Service, Source, Product, and Country/Sub-Region)
  • GCC
  • South Africa
  • Rest of the Middle East & Africa

Table of Content

1. Introduction

• 1.1. Research Scope
• 1.2. Market Segmentation
• 1.3. Research Methodology
• 1.4. Definitions and Assumptions

2. Executive Summary

3. Market Dynamics

• 3.1. Market Drivers
• 3.2. Market Restraints
• 3.3. Market Opportunities
• 3.4. Market Trends

4. Key Insights

• 4.1. Technological Advancements in Biopharmaceutical CMO
• 4.2. Key Industry Developments (Mergers, Acquisitions, Partnerships, etc.)
• 4.3. Overview: Regulatory Scenario, By Key Countries/Regions
• 4.4. Impact of COVID 19 on the Market

5. Global Biopharmaceutical CMO Market Analysis, Insights and Forecast, 2021-2034

• 5.1. Market Analysis, Insights and Forecast - By Service
  • 5.1.1. Manufacturing
    • 5.1.1.1. Upstream Processing
    • 5.1.1.2. Downstream Processing
  • 5.1.2. Fill & Finish Operations
  • 5.1.3. Analytical & QC Studies
  • 5.1.4. Packaging
• 5.2. Market Analysis, Insights and Forecast - By Source
  • 5.2.1. Mammalian
  • 5.2.2. Non-Mammalian
• 5.3. Market Analysis, Insights and Forecast - By Product
  • 5.3.1. Biologics
  • 5.3.2. Biosimilars
• 5.4. Market Analysis, Insights and Forecast - By Region
  • 5.4.1. North America
  • 5.4.2. Europe
  • 5.4.3. Asia Pacific
  • 5.4.4. Latin America
  • 5.4.5. Middle East & Africa

6. North America Biopharmaceutical CMO Market Analysis, Insights and Forecast, 2021-2034

• 6.1. Market Analysis, Insights and Forecast - By Service
  • 6.1.1. Manufacturing
    • 6.1.1.1. Upstream Processing
    • 6.1.1.2. Downstream Processing
  • 6.1.2. Fill & Finish Operations
  • 6.1.3. Analytical & QC Studies
  • 6.1.4. Packaging
• 6.2. Market Analysis, Insights and Forecast - By Source
  • 6.2.1. Mammalian
  • 6.2.2. Non-Mammalian
• 6.3. Market Analysis, Insights and Forecast - By Product
  • 6.3.1. Biologics
  • 6.3.2. Biosimilars
• 6.4. Market Analysis, Insights and Forecast - By Country
  • 6.4.1. U.S.
  • 6.4.2. Canada

7. Europe Biopharmaceutical CMO Market Analysis, Insights and Forecast, 2021-2034

• 7.1. Market Analysis, Insights and Forecast - By Service
  • 7.1.1. Manufacturing
    • 7.1.1.1. Upstream Processing
    • 7.1.1.2. Downstream Processing
  • 7.1.2. Fill & Finish Operations
  • 7.1.3. Analytical & QC Studies
  • 7.1.4. Packaging
• 7.2. Market Analysis, Insights and Forecast - By Source
  • 7.2.1. Mammalian
  • 7.2.2. Non-Mammalian
• 7.3. Market Analysis, Insights and Forecast - By Product
  • 7.3.1. Biologics
  • 7.3.2. Biosimilars
• 7.4. Market Analysis, Insights and Forecast - By Country/Sub-region
  • 7.4.1. Germany
  • 7.4.2. France
  • 7.4.3. U.K.
  • 7.4.4. Italy
  • 7.4.5. Spain
  • 7.4.6. Scandinavia
  • 7.4.7. Rest of Europe

8. Asia Pacific Biopharmaceutical CMO Market Analysis, Insights and Forecast, 2021-2034

• 8.1. Market Analysis, Insights and Forecast - By Service
  • 8.1.1. Manufacturing
    • 8.1.1.1. Upstream Processing
    • 8.1.1.2. Downstream Processing
  • 8.1.2. Fill & Finish Operations
  • 8.1.3. Analytical & QC Studies
  • 8.1.4. Packaging
• 8.2. Market Analysis, Insights and Forecast - By Source
  • 8.2.1. Mammalian
  • 8.2.2. Non-Mammalian
• 8.3. Market Analysis, Insights and Forecast - By Product
  • 8.3.1. Biologics
  • 8.3.2. Biosimilars
• 8.4. Market Analysis, Insights and Forecast - By Country/Sub-region
  • 8.4.1. China
  • 8.4.2. India
  • 8.4.3. Japan
  • 8.4.4. Australia
  • 8.4.5. Southeast Asia
  • 8.4.6. Rest of Asia Pacific

9. Latin America Biopharmaceutical CMO Market Analysis, Insights and Forecast, 2021-2034

• 9.1. Market Analysis, Insights and Forecast - By Service
  • 9.1.1. Manufacturing
    • 9.1.1.1. Upstream Processing
    • 9.1.1.2. Downstream Processing
  • 9.1.2. Fill & Finish Operations
  • 9.1.3. Analytical & QC Studies
  • 9.1.4. Packaging
• 9.2. Market Analysis, Insights and Forecast - By Source
  • 9.2.1. Mammalian
  • 9.2.2. Non-Mammalian
• 9.3. Market Analysis, Insights and Forecast - By Product
  • 9.3.1. Biologics
  • 9.3.2. Biosimilars
• 9.4. Market Analysis, Insights and Forecast - By Country/Sub-region
  • 9.4.1. Brazil
  • 9.4.2. Mexico
  • 9.4.3. Rest of Latin America

10. Middle East & Africa Biopharmaceutical CMO Market Analysis, Insights and Forecast, 2021-2034

• 10.1. Market Analysis, Insights and Forecast - By Service
  • 10.1.1. Manufacturing
    • 10.1.1.1. Upstream Processing
    • 10.1.1.2. Downstream Processing
  • 10.1.2. Fill & Finish Operations
  • 10.1.3. Analytical & QC Studies
  • 10.1.4. Packaging
• 10.2. Market Analysis, Insights and Forecast - By Source
  • 10.2.1. Mammalian
  • 10.2.2. Non-Mammalian
• 10.3. Market Analysis, Insights and Forecast - By Product
  • 10.3.1. Biologics
  • 10.3.2. Biosimilars
• 10.4. Market Analysis, Insights and Forecast - By Country/Sub-region
  • 10.4.1. GCC
  • 10.4.2. South Africa
  • 10.4.3. Rest of Middle East & Africa

11. Competitive Analysis

• 11.1. Global Market Share Analysis (2025)
• 11.2. Company Profiles
  • 11.2.1. Thermo Fisher Scientific Inc.
    • 11.2.1.1. Overview
    • 11.2.1.2. Services
    • 11.2.1.3. SWOT Analysis
    • 11.2.1.4. Recent Developments
    • 11.2.1.5. Strategies
    • 11.2.1.6. Financials (Based on Availability)
  • 11.2.2. Wuxi Biologics
    • 11.2.2.1. Overview
    • 11.2.2.2. Services
    • 11.2.2.3. SWOT Analysis
    • 11.2.2.4. Recent Developments
    • 11.2.2.5. Strategies
    • 11.2.2.6. Financials (Based on Availability)
  • 11.2.3. Lonza
    • 11.2.3.1. Overview
    • 11.2.3.2. Services
    • 11.2.3.3. SWOT Analysis
    • 11.2.3.4. Recent Developments
    • 11.2.3.5. Strategies
    • 11.2.3.6. Financials (Based on Availability)
  • 11.2.4. Recipharm AB
    • 11.2.4.1. Overview
    • 11.2.4.2. Services
    • 11.2.4.3. SWOT Analysis
    • 11.2.4.4. Recent Developments
    • 11.2.4.5. Strategies
    • 11.2.4.6. Financials (Based on Availability)
  • 11.2.5. Catalent Inc.
    • 11.2.5.1. Overview
    • 11.2.5.2. Services
    • 11.2.5.3. SWOT Analysis
    • 11.2.5.4. Recent Developments
    • 11.2.5.5. Strategies
    • 11.2.5.6. Financials (Based on Availability)
  • 11.2.6. FUJIFILM Corporation (FUJIFILM Diosynth Biotechnologies)
    • 11.2.6.1. Overview
    • 11.2.6.2. Services
    • 11.2.6.3. SWOT Analysis
    • 11.2.6.4. Recent Developments
    • 11.2.6.5. Strategies
    • 11.2.6.6. Financials (Based on Availability)
  • 11.2.7. Cambrex Corporation
    • 11.2.7.1. Overview
    • 11.2.7.2. Services
    • 11.2.7.3. SWOT Analysis
    • 11.2.7.4. Recent Developments
    • 11.2.7.5. Strategies
    • 11.2.7.6. Financials (Based on Availability)
  • 11.2.8. Samsung Biologics
    • 11.2.8.1. Overview
    • 11.2.8.2. Services
    • 11.2.8.3. SWOT Analysis
    • 11.2.8.4. Recent Developments
    • 11.2.8.5. Strategies
    • 11.2.8.6. Financials (Based on Availability)
  • 11.2.9. Siegfried Holding AG
    • 11.2.9.1. Overview
    • 11.2.9.2. Services
    • 11.2.9.3. SWOT Analysis
    • 11.2.9.4. Recent Developments
    • 11.2.9.5. Strategies
    • 11.2.9.6. Financials (Based on Availability)